GSK in the news as UK pharma giant eyes more UK investment after pharma deals—Emma Walmsley-led firm persists in global drug growth.
GSK has struck a multi-billion deal to acquire Nuvalent, adding three late-stage cancer drugs to its portfolio, including two lung-cancer therapies under FDA review. The acquisition aims to boost sales growth, expand the lung-cancer platform, and position GSK for a potential rise in annual revenue by 2031.